title: Central nervous system T-cell lymphoma in acquired immunodeficiency syndrome.
authors.forename: Mihoko
authors.initials: M
authors.lastname: Yotsumoto
authors.forename: Kotaro
authors.initials: K
authors.lastname: Funato
authors.forename: Yuko
authors.initials: Y
authors.lastname: Hashimoto
authors.forename: Hiroaki
authors.initials: H
authors.lastname: Fujimoto
authors.forename: Katsuyuki
authors.initials: K
authors.lastname: Fukutake
mesh_terms: D000163:Acquired Immunodeficiency Syndrome / Q000150:complications*; D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use; D023241:Antiretroviral Therapy, Highly Active; D001921:Brain / Q000473:pathology; D016543:Central Nervous System Neoplasms / Q000175:diagnosis* / Q000188:drug therapy; D006801:Humans; D019259:Lamivudine / Q000627:therapeutic use; D016399:Lymphoma, T-Cell / Q000175:diagnosis* / Q000188:drug therapy; D008279:Magnetic Resonance Imaging; D008297:Male; D008727:Methotrexate / Q000627:therapeutic use; D011760:Pyrrolidinones / Q000627:therapeutic use; D000068898:Raltegravir Potassium; D018119:Stavudine / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D011760:Pyrrolidinones; D019259:Lamivudine; D000068898:Raltegravir Potassium; D018119:Stavudine; D008727:Methotrexate